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ABSTRACT
Volumetric modulated arc therapy (VMAT) is a rotational IMRT technique that uses a
radiotherapy linear accelerator gantry with a dynamic MLC, variable dose rate, and variable
gantry speed. These new degrees of freedom of VMAT delivery introduced complexities for
treatment planning, and Pinnacle3 SmartArc treatment module was recently developed as a
solution. However, it was unclear how varying each SmartArc parameter affected the resulting
plan quality. The purpose of this study was to systematically examine all planning parameters
and quantify the effect of varying each on the quality of a reference plan.
Parameters were separated into two categories: commissioning parameters and planning
parameters. Commissioning parameters were those available to the user during the machine
commissioning process in Pinnacle, i.e. dose rate, gantry speed, MLC size, and MLC speed.
Planning parameters were those available to the user during routine treatment planning, i.e. beam
energy, collimator angle, arc length, and final gantry spacing. A "baseline" set of commissioning
and planning parameters was created that provided clinically acceptable plans for a cylindrical
phantom case, simple prostate case, and complex (multi-target) prostate case. Each parameter
was independently varied while keeping all other parameters set to the baseline values. The
resulting change in each plan was evaluated using dose volume histograms, dose homogeneity
indices (DHI), conformity indices (CI) and normal tissue dose metrics.
The DHI and CI for the phantom and simple prostate cases varied by less than 0.02 from
the baseline values for most parameters. The DHI and CI for the complex prostate case varied
by more than 0.02 from the baseline values for most parameters. The dose to normal tissues
changed by less than 3% as parameters were varied for the simple prostate case and more than
3% as parameters were varied for the complex prostate case.

v

Most SmartArc parameters had little effect on DHI, CI, and normal tissue sparing for the
phantom and simple prostate treatment geometries, but showed significant variations for the
complex prostate case. We conclude that SmartArc optimization is largely user-independent and
hardware-independent for non-complex prostate treatment geometries. However, certain
parameters (especially planning parameters) create a significant change in resulting plan quality
for complex prostate treatment geometries.

vi

1 INTRODUCTION
1.1 Background and Significance
1.1.1 History and Development of VMAT
Intensity modulated arc therapy (IMRT) is a radiation treatment modality that provides
accurate, reliable, and highly conformal dose to a planning target volume (Khan 2003). Several
techniques of delivering IMRT have been established: static-gantry techniques, such as fixedbeam IMRT; and rotational-gantry techniques, such as helical tomotherapy (Mackie et al. 1993;
Bortfeld and Webb 2009). Fixed-beam IMRT has been shown to provide better dose
conformality and normal tissue sparing than 3-D conformal treatments (Staffurth 2010), but it is
still limited by only using a finite number of beams for delivery. Helical tomotherapy also
provides highly conformal dose distributions, but requires specialized delivery hardware and
treatment planning software. Both fixed-beam IMRT (except for compensator-based IMRT) and
helical tomotherapy increase treatment delivery time compared to 3-D conformal treatments,
which could lead to greater problems in dose accuracy due to intra-fractional motion.
The idea of using a traditional linear accelerator gantry for a rotational IMRT treatment
was first suggested by Yu et al. in 1995 as an alternative to tomotherapy, which necessitated
specialized equipment and struggled with abutment problems between treatment slices at that
time. Yu's alternative was called intensity modulated arc therapy (IMAT) and utilized a large
field size, traditional linear accelerator, continuous gantry rotation, and dynamic MLC. To
create an intensity distribution, IMAT was delivered in multiple overlapping arcs. Each arc
delivered only one level of intensity; therefore multiple arcs were required for multiple levels of
intensity. The two-dimensional intensity distribution at each angle was a composition of
multiple radiation fields of uniform intensity with different shapes and sizes. Shortly after IMAT
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was proposed, helical tomotherapy was created, alleviating abutment problems without the
necessity of developing new software for optimization and delivery of IMAT. As such, IMAT
was never used in mainstream clinical practice.
Developments in rotational delivery capabilities of traditional linear accelerators in the
last few years, specifically variable dose rate and variable gantry speed, have sparked a new
interest in rotational IMRT delivery and IMAT (Bortfeld and Webb 2009). Volumetric
modulated arc therapy (VMAT) has been developed using the basic principles of IMAT, coupled
with these new machine capabilities. During a VMAT treatment, MLC leaves dynamically
shape the beam to treat the entire volume of the planning target volume (PTV) with every
rotation, and the dose rate and/or gantry rotation speed is continuously varied as the gantry of the
linear accelerator rotates around the patient. Because of the ability of the linear accelerator to
vary dose rate and gantry speed during rotation, it is no longer necessary to use multiple
overlapping arcs to create modulated intensity, and an entire fraction of treatment can often be
delivered in a single arc (Bortfeld and Webb 2009).
Both Elekta, Inc. (Stockholm, Sweeden) and Varian Medical Systems (Palo Alto,
California) have developed VMAT capabilities on their traditional linear accelerators. Varian
has named this new version of VMAT "RapidArc," while Elekta refers to it as "VMAT." In this
study "VMAT" is used as a generic term for a dynamic arc IMRT treatment modality that uses
dynamic MLC, variable dose rate, and variable gantry speed, and is not meant to be vendorspecific.
1.1.2 Technical Description of VMAT
Three key components of VMAT are rotational delivery, dynamic MLC, and variable
dose rate and gantry speed. To describe these components, it is useful to compare and contrast
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VMAT to both fixed-beam IMRT and tomotherapy. Although VMAT and tomotherapy are both
rotational treatment modalities, their delivery methods are very different. Tomotherapy,
meaning ‘slice therapy,’ uses a fan beam and ring gantry to treat one transverse slice of the PTV
at a time (Mackie et al. 1993). In helical tomotherapy, much like helical computed tomography,
the couch moves perpendicularly to the gantry plane while the gantry rotates around the patient,
creating a spiral-treatment (Yang et al. 1997). With VMAT, however, the entire PTV is treated
with every rotational pass of the gantry (Cao et al. 2007). This means VMAT has the potential
to treat the entire PTV to the desired dose using a single arc (Otto 2008). In other words,
tomotherapy can be considered a planar delivery technique, whereas VMAT is a volumetric

Figure 1-1. Tomotherapy slice delivery (left) vs. VMAT volumetric delivery (right).
delivery technique. A schematic of the difference in delivery is shown in Figure 1-1. Both
gantries rotate around the patient, but the tomotherapy couch moves into the gantry to create a
helical slice delivery while the VMAT couch remains stationary as the beam treats the entire
PTV.
The next key component of VMAT treatments is the dynamic MLC. Treatment plans for
fixed-beam IMRT are comprised of a finite number of beams at fixed angles around the patient.
3

In order to produce an optimized fluence pattern for each fixed beam, the MLC leaves move
either dynamically (Svensson et al. 1994) or in a step-and-shoot fashion (Wu et al. 2001) across

Figure 1-2. Sample MLC segments for VMAT delivery for 6 consecutive control
points. MLC leaves (white) do not simply follow the shape of the PTV (red) as the
gantry rotates around the patient.
the beam, creating several segments with different intensities to modulate the beam.
Compensator-based IMRT does not use MLCs, but instead a tissue compensator is fabricated for
every beam angle and attached to the machine before the beam is delivered. In tomotherapy
treatments, beams are optimized for 51 arc segments in each slice, and the binary MLC leaves
are either open or closed for some specific amount of time during the arc segment in order to
modulate the beam (Mackie et al. 1993). For both fixed-beam IMRT and helical tomotherapy,
the beam modulation is determined by the amount of time the leaves spend in each position.
VMAT treatments must use a dynamic MLC because the beam is on during the entire treatment
as the gantry rotates around the patient. For VMAT treatments, the MLC leaves move as a
4

function of gantry position, not time (Bortfeld and Webb 2009). The leaves reposition according
to where the gantry is located in its rotation, and each angle of rotation sees only one segment
shaped by the MLC. However, because the leaves do not simply conform to the shape of the
PTV, VMAT can still be considered a form of IMRT, not 3-D conformal therapy. An example
of MLC segment positions as the gantry travels around the arc is shown in figure 1-2. The
leaves are used to modulate the intensity distribution.
Rotational delivery adds the flexibility of treating at every angle, which can be greatly
advantageous for some treatment sites, but the limited MLC range of motion per gantry angle
somewhat limits this flexibility (Otto 2008). Because the MLC leaves have a maximum speed,
the distance they travel is limited by how slowly the gantry can rotate. Limited leaf motion and
continuous beam delivery can quickly lead to unwanted dose to normal tissues. To obtain a
sufficient intensity resolution without the necessity of using overlapping arcs (Yu 1995; Earl et
al. 2003), the dose rate and/or gantry speed are varied throughout the VMAT treatment. This
creates a direct modulation of beam output that is unique to VMAT delivery. During VMAT
treatment, the beam output is changed according to gantry position, whereas intensity modulation
in both tomotherapy and fixed-beam IMRT results from changing the beam-on time for each
MLC segment. VMAT delivery combines varying leaf motion with varying dose rate and/or
gantry rotation speed to modulate beam intensity.
1.1.3 Advantages and Disadvantages of VMAT
The most frequently-mentioned and advertised benefits of VMAT are decreased
treatment time and increased monitor unit (MU) efficiency. If only a single arc is used, the
beam-on time is reduced to the time it takes the gantry to rotate from the start angle to the stop
angle position (including variations in gantry speed). This can accomplish a substantially shorter
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overall treatment time than both helical tomotherapy and fixed-beam IMRT (Webb and McQuaid
2009). It has been shown that for prostate and head and neck treatment sites, VMAT plans with
similar or better quality than fixed-beam IMRT could be delivered in less than 3 minutes,
compared to 8-12 minutes for fixed-beam IMRT delivery (Bzdusek et al. 2009; Verbakel et al.
2009; Shaffer et al. 2009; Zhang et al. 2009). The shorter overall treatment time has been
advertised to lead to greater patient compliance as well as greater throughput for the radiation
treatment facility. Alternatively, shorter beam-on time may allow for use of more advanced
image-guidance tools, such as on-board cone beam computed tomography that is now becoming
widely available, without sacrificing overall treatment time.
VMAT also has much higher MU efficiency than other forms of IMRT delivery, with the
exception of compensator-based IMRT. This means VMAT can treat the PTV to the same dose
using fewer MU than fixed-beam IMRT and helical tomotherapy. Fixed-beam IMRT and
tomotherapy keep the dose rate constant and change the amount of beam-on time for each MLC
segment to modulate intensity. With these techniques, much of the beam is “wasted” for small
fields. Because VMAT directly varies the dose rate of the beam to change the beam’s intensity,
it is much more efficient in terms of MUs than both tomotherapy and fixed-beam IMRT.
Verbakel et al. found that VMAT reduced the number of monitor units used per fixed-beam
IMRT treatment by 40 percent for head and neck geometries (2009). Bzdusek found MUs were
decreased up to 23 percent for lung geometries, 13 percent for whole brain, and less than 10%
for tonsil and prostate, where MU for one of three prostate cases actually increased 29 percent
(2009). Also, photon x-ray beams with energy less than 10MV are typically used for IMRT
because IMRT treatments require more MUs than conformal treatments, causing increased
secondary radiation to normal tissues outside the radiation field due to leakage and scatter. For
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energies greater than 10MV, neutron production from photon interactions in the machine head
also increases with increasing MU (Reft et al. 2006). By requiring fewer MUs, VMAT can
potentially allow for usage of higher energy photons with reduced risk of secondary cancers.
Disadvantages of VMAT include a limited beam size, which makes VMAT incapable of
treating long PTVs (e.g. craniospinal cases) without abutment of two arcs. Also, multiple
superimposed arcs may be required for VMAT to achieve comparable modulation and dose
distributions to those achieved by Tomotherapy.
1.2 Optimization of VMAT
Along with the evolution of rotational delivery capabilities of the treatment machine,
substantial changes in the optimization algorithms used for fixed-beam IMRT were necessary in
order to make VMAT clinically possible. These included techniques for creating an effective
360 degree fluence map and the addition of several new optimization parameters. The
optimization module used in this study was SmartArc, developed for the Pinnacle3 treatment
planning system (Philips Medical Systems, Andover, MA).
Though the beam treats in a continuous arc, there are a finite number of control points
(CPs), or samples around the arc used for optimization and delivery. This produces a tradeoff
between dose delivery accuracy and optimization computation time (Otto 2008); more CPs leads
to better plan accuracy but longer computation time. Otto proposed implementing “progressive
sampling” as a compromise. First, coarse sampling is used to create intensity maps for several
angles around the arc, and then subsequent CPs are added in smaller degree increments to
increase plan dosimetric accuracy. Figure 1-3 shows a diagram of progressive sampling.
Bzdusek et al. (2009) incorporated progressive sampling in their VMAT optimization
solution for the SmartArc treatment planning module. First, an initial coarse sampling increment
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Figure 1-3. Diagram of progressive sampling. An initial coarse CP spacing is chosen (a)
and intermediate CPs are added between existing CPs until desired CP frequency is
reached (b-d). Figure reprinted from Otto 2007, Medical Physics, Vol. 35 p 312
of 24 degrees is used, and fluence maps are generated, optimized, and converted to leaf segments
for these angles. Then, intermediate MLC segments are linearly interpolated between the coarse
segments, creating a finer CP spacing (Bzdusek et al. 2009).
SmartArc optimization module is outlined in Figure 1-4. First, intensity maps are
optimized every 24 degrees around the arc and converted to 2-4 different MLC segments. The

Figure 1-4. Outline of SmartArc optimization. Figure
reprinted from Bzdusek et al. 2009, Medical Physics, Vol.
36 p 2330
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two MLC segments that have the most open space are selected and redistributed 8 degrees above
and below the point along the arc where the intensity map was initially created (every 24
degrees). The two segments with the most open space are selected in order to minimize leaf
travel between CPs. The remaining MLC segments generated for that point are discarded.
Additional MLC segments are then linearly interpolated to create the CP resolution, or final
gantry spacing, selected by the user (2, 3, 4, or 6 degrees). Figure 1-5 shows the filtering,
redistribution and sequencing of MLC segments.

Figure 1-5. Diagram of MLC segment creation for SmartArc
optimization. 2-4 segments are generated at the initial CP spacing
(24º), then 2 are selected and redistributed (crosses) while the
others are discarded. Additional MLC segments are interpolated
between the initial segments (first blue circles, then red). Figure
reprinted from Bzdusek et al. 2009, Medical Physics, Vol. 36 p 2330
After initial arc MLC segments have been interpolated, machine parameters are
optimized, followed by a convolution dose calculation and segment weight optimization. Then
the process is repeated until the number of iterations is reaches its limit. The result is that every
2, 3, 4, or 6 degrees, the treatment control system is given a new set of directions until it arrives
at the next CP. The set of directions includes MLC configuration, leaf speed, dose rate and
gantry rotation speed.
9

1.3 Motivation for Research
Clinical treatment planning requires commercialized software and tested protocols to
accurately construct radiation therapy treatment plans that maximize the capabilities of available
technology. While such tools have long been established for tomotherapy and fixed-beam
IMRT, analogous tools for VMAT are still in the development stages. Recently a commercial
utility, Phillips Pinnacle3 SmartArc (described above), has been created to optimize VMAT
treatments; however, the optimization process contains numerous parameters and options that
have not yet been fully explored (Bzdusek et al. 2009). It is currently unknown how each of
these parameters may be used to generate an optimal treatment plan for any particular treatment
site.
The goal of this study was to systematically vary and examine new parameters introduced
by VMAT (such as variable dose rate) and previously existing parameters (such as maximum
gantry speed) that had potential to influence resulting VMAT plans. A comprehensive study of
all parameters related to VMAT treatment planning is clinically relevant and useful for future
treatment planning.
1.4 Hypothesis and Specific Aims
Our hypothesis was that a set of parameters for the Phillips Pinnacle3 SmartArc treatment
planning module could be determined that produce dynamic arc plans with
1) treatment times less than half that of corresponding fixed-beam IMRT plans, and
2) better than !3% dose homogeneity in the PTV of a water phantom, !5% dose
homogeneity in the PTV of a simple prostate patient, and !5% dose homogeneity in the
primary PTV of a multi-target complex prostate patient
while maintaining sufficient sparing of critical structures.
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Specific Aim 1: Determine a set of baseline parameters for planning VMAT
treatment for a spherical PTV in a simple water-equivalent phantom, and then vary
parameters systematically. The baseline plan was considered acceptable if it maintained !3%
dose homogeneity within the PTV. All parameters were kept identical to the baseline set except
the parameter actively being studied.
Specific Aim 2: Determine a set of baseline parameters for planning VMAT
treatment for a simple prostate patient, and then vary parameters systematically. A
previously treated, simple prostate patient involving a single target was selected. The baseline
plan was considered acceptable if it maintained !5% dose homogeneity within the PTV and
sufficiently spared surrounding critical structures.
Specific Aim 3: Determine a set of baseline parameters for planning VMAT
treatment for a complex, multi-target prostate patient, and then vary parameters
systematically. A previously treated, complex prostate patient involving multiple targets was
selected. The baseline plan was considered acceptable if it maintained !5% dose homogeneity
within the PTV and sufficiently spared surrounding critical structures.
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2 METHODS
To determine how optimization parameters affect resulting plan quality, parameters were
varied and resulting plans evaluated for three treatment sites with increasing complexity. All
cases were planned and optimized using Pinnacle3 version 8.1y (Philips Medical Systems,
Andover, MA). Version 8.1y was the first release of Pinnacle to include the SmartArc planning
module, and it was the most current version at the time of the study. All parameters used in this
study are introduced here, followed by a detailed description of the methods common to all
specific aims and, finally, an explanation of details unique to each specific aim.
2.1 Description of Parameters
2.1.1 Commissioning Parameters
A list of parameters relevant to SmartArc planning was created and categorized into two
groups: commissioning parameters and planning parameters. Commissioning parameters were
those parameters available for selection during the commissioning and configuration of the linear
accelerator in the treatment planning system. These parameters included dose rate, gantry speed,
MLC size and maximum leaf speed, and maximum MU per degree of rotation. These
parameters are typically chosen based on the physical and mechanical capabilities of the linear
accelerator used for treatment, and are briefly described here:
"

Dose rate is a measure of the output of the beam in MU per time. The Philips Pinnacle
treatment planning system allows for the dose rate to be varied either continuously or
discretely. The user must also specify a maximum allowable dose rate. If the dose rate is
varied continuously, the user must only provide the maximum allowable dose rate as
input to Pinnacle. If the dose rate is varied discretely, the user must provide each
allowable dose rate in a table provided in the commissioning window of Pinnacle. Elekta
linear accelerators vary dose rate discretely, stepping down from the maximum dose rate
12

by a factor of two until reaching some minimum dose rate (i.e. 600, 300, 150, 75, 37
MU/min). Varian linear accelerators, however, have a continuously variable dose rate.
In this study, trials for both continuously variable and discretely variable dose rates were
examined for maximum dose rates of 400, 600 and 800 MU/min.
"

Maximum gantry speed describes the maximum angular velocity of the gantry, and is
given in units of degrees per second. The maximum gantry speed would theoretically
influence resulting VMAT plans because the gantry is continuously rotating as the beam
is continuously delivering. A faster maximum speed implies the possibility of a shorter
overall delivery and perhaps a better dose distribution. The faster gantry lowers the
minimum possible dose delivered per control point arc. Maximum gantry speeds of 4, 6,
8, and 12 deg/sec were used in this study.

"

Maximum MLC leaf speed is a measure of how far the leaves can travel in a certain
amount of time in units of cm/sec. The relevance of this parameter is connected to gantry
rotation speed. The distance the leaves can travel per gantry rotation determines how
much the beam shape can change between control points, and how much the beam can be
modulated by the MLC. Only IMRT delivery techniques using dynamic MLC would be
influenced by this parameter. Maximum MLC leaf speeds used in the study were 1, 2,
and 3 cm/sec.

"

MLC leaf size describes the width of the individual MLC leaves and varies among linear
accelerator vendors. Leaves in the 80-leaf MLC of Elekta linear accelerators have 1cm
thickness, while the 120-leaf Varian MLC combines 5mm leaves in the center of the field
with 1cm leaves toward the edges of the field. It would be intuitive to assume a smaller
MLC leaf size would produce a more conformal dose to the PTV and spare normal
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tissues surrounding the PTV more effectively. In fact, it has been shown that this is not
necessarily the case for fixed-beam IMRT (Su et al. 2007). Leaf widths of 1cm and 5mm
were both used in this study.
"

Maximum MU/degree limits how much output the beam can deliver per degree of
rotation. The starting value for this study was 100 MU/deg, and then 1 MU/deg was
chosen to determine how the optimization algorithm would respond to an unreasonably
low value.

Commissioning parameters do not necessarily have an effect on optimization of fixed-beam
IMRT treatments. For example, the leaf speed and gantry rotation do not affect the plan quality
of a step-and-shoot treatment because the leaves are not moving and the gantry is not rotating
while the dose is being delivered. However, commissioning parameters could have an important
influence on plan quality for VMAT treatments because the gantry rotates and the MLC moves
continuously during beam delivery. A list of commissioning parameters and the range of values
for which each parameter was varied is given in Table 2-1. The intervals of values chosen for
parameter variation were selected to bind the possible capabilities of a linear accelerator around a
Table 2-1. List of commissioning parameters and range
of values used in the study. Baseline values shown in
bold type.
Commissioning Parameters
Gantry Speed Variability
Maximum Gantry Speed
Maximum Dose Rate
Dose Rate Variability
Maximum MLC Leaf Speed

Range of values
yes/no
4, 6, 8, 12 deg/sec
400, 600, 800 MU/min
Continuous/Discrete
1, 2, 3 cm/sec

MLC Leaf Size
Maximum MU/degree

1cm/5mm
1, 100 MU/deg
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baseline value, shown in bold type in Table 2-1. Baseline values were chosen according to
recommendations from Pinnacle (Friberger 2009) and existing machine capabilities.
2.1.2 Planning Parameters
Planning parameters were defined as those parameters available for selection during
routine treatment planning. Planning parameters examined in this work included beam energy,
arc length, collimator angle, dose grid resolution, final gantry spacing, and maximum delivery
time, and are briefly described here:
"

Beam energy depends on a selection of megavoltage energies available for any specific
machine. The machine used in the present study had 6, 10, and 15 MV energies
available.

"

Arc length is determined by setting the start and stop angle of the continuous arc.
Pinnacle version 8.1y used in this study could only optimize for a single, maximum 360degree arc. For this study, total arc lengths were varied to 60, 120, 180, 270, and 360
degrees.

"

Collimator angle ranges from 0 to 360 degrees and remains stationary throughout the
entire treatment. MLC leaves move in only one dimension, so the collimator can move
parallel to gantry rotation direction (90 degree collimator angle for this study) or
perpendicular to gantry rotation direction (0 degree collimator angle for this study) or at
some angle in between. A 45 degree collimator angle covers the longest distance in the
superior-inferior dimension. Collimator angles of 0-90 degrees represent a complete
range of collimator orientations with respect to gantry rotation direction. For instance,
collimator angles of 0 and 180 degrees represent the same orientation to gantry rotation,
and collimator angles of 90 and 270 degrees represent the same orientation to gantry
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rotation. For this reason, only collimator angles ranging from 0 to 90 degrees were used
in this study.
"

Dose grid resolution determines the dose calculation sampling resolution for the Pinnacle
treatment planning system. The standard dose grid resolution used in our treatment
facility is 0.400 cm. Dose grid resolution was also varied to 0.300cm and 0.500 cm to
determine the effects on resulting plan quality.

"

Final gantry spacing is the final spacing of control points around the VMAT delivery arc.
Because of progressive sampling, described earlier, the optimization always starts at a 24
degree spacing of control points, and the final spacing is chosen by the user to be 2, 3, 4,
or 6 degrees.

"

Maximum delivery time is requested by the user to keep overall treatment time less than
some maximum value. Maximum delivery times used in this study were 60, 120, and
240 seconds for all treatment geometries, with varying supplemental treatment times for
each geometry.

"

Allow backup jaw motion parameter determines if the jaws remain stationary or if they
are allowed to follow the MLC leaves during treatment. Allowing back-up jaw motion
during optimization created an artifact in the computed final dose in version 8.1y, so jaws
were opened enough to cover the PTV with a 0.5cm margin from all gantry angles at
specified collimator setting and fixed in position for optimization for this study. In more
recent versions of Pinnacle (9.0), this problem has been resolved.

Planning parameters are not necessarily limited by linear accelerator capabilities, but are an
integral part of the optimization process for SmartArc treatment planning. They are typically
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variable within the machine’s capabilities and chosen by the planner to create the best possible
plan.
In addition to planning parameters used for several different delivery techniques, there
are a few planning parameters specific to SmartArc optimization. One of these parameters, final
gantry spacing, determines the final spacing of control points around the delivery arc. Maximum
delivery time is also unique to SmartArc optimization and allows the user to minimize overall
treatment time per treatment fraction. A complete list of planning parameters used in this study
and the interval of values for which they were varied is given in Table 2-2. Baseline values are
shown in bold type. These values were chosen according to recommendations by Pinnacle and
common values used for fixed-beam IMRT in our treatment facility.
Table 2-2. List of planning parameters and range of
values used in this study. Baseline values are shown in
bold type.
Planning Parameters
Beam Energy
Arc Length
Collimator angle
Dose grid resolution
Maximum delivery time
Final gantry spacing

Range of values
6, 10, 15 MV
60, 120, 180, 270, 360 deg
0, 30, 45, 60, 90 deg
0.3, 0.4, 0.5 cm
60, 120, 240 sec
2, 3, 4, 6 deg

2.2 Research Design
This study focused on three treatment sites to determine the effect of varying each of the
previously mentioned parameters on plan quality: a spherical target within a cylindrical phantom,
a single-target prostate, and a multi-target prostate. Each of the three specific aims tested the
hypothesis for one and only one of these treatment sites. The process for creating treatment
plans and evaluating commissioning and planning parameters was common to all aims and is
described in the following paragraphs. First, a clinically acceptable baseline plan was generated
for each treatment geometry. Then, parameters were varied independently and systematically
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from their baseline values. Finally target homogeneity data, conformity data, and normal tissue
data were collected in order to quantify and evaluate the quality of resulting plans.
2.2.1 Baseline Plan
For each treatment site, a baseline plan was created that provided acceptable dose
homogeneity and sufficient normal tissue sparing. To determine sufficient normal tissue sparing
and clinical acceptability, all baseline plans were approved by a radiation oncologist. Initial
parameter values for each baseline plan were set based on recommendations from Pinnacle or
taken as values from an Elekta linear accelerator used for IMRT treatment at our facility.
Baseline parameter values are shown in Table 2-3.
Table 2-3. Baseline parameter values for all three
treatment geometries.
Parameter
Gantry Speed Variability
Maximum Gantry Speed
Maximum Dose Rate
Dose Rate Variability
Maximum MLC Leaf Speed

Baseline Value
yes
6 deg/sec
600 MU/min
Discrete
2 cm/sec

MLC Leaf Size
Maximum MU/degree
Beam Energy
Arc Length
Collimator angle
Dose grid resolution
Maximum delivery time
Final gantry spacing

1cm
100 MU/deg
6 MV
360 deg
0 (prostate), 90 (phantom) deg
0.4 cm
120 sec
4 deg

2.2.2 Parameter Variation
Once a baseline plan was created, all commissioning and planning parameters were
varied systematically. Figure 2-1 shows a diagram of how each parameter was varied. After the
treatment geometry was selected and the baseline parameter values were chosen, the baseline
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plan was copied several times, creating a new plan for each parameter in order to study
parameters separately.

Figure 2-1. Diagram of steps taken to create new trials for each parameter studied. First
patient geometry is selected, then a baseline plan is created and copied several times to create a
new plan for each parameter studied. The baseline trial is then copied within each plan in order
vary that parameter while keeping all other parameters set to their baseline values.
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Several trials were created within each plan corresponding to different input values for
that parameter. For example, a plan entitled “Maximum gantry speed” was created for each
patient, and several trials were created inside that plan with different maximum gantry speeds.
To examine commissioning parameters, it was necessary to commission a new machine for each
trial.
Copying the baseline plan generated a baseline trial within every plan. Each parameter
was varied from a copy of this baseline trial. In other words, the baseline plan was copied
several times to create new plans (one plan for every commissioning and planning parameter),
and the baseline trial was copied several times to create new trials within those plans. This
assured that all parameters remained fixed at the baseline values except for the parameter being
studied in that plan. The number of trials in each plan depended on the range of variability of the
parameter being studied. Some parameters consisted of a yes or no option; therefore these plans
contained only two trials. The range of variability was chosen to expand above and below the
baseline value for each parameter, and is shown for commissioning and planning parameters in
Tables 2-1 and 2-2. Table 2-1 shows 6 commissioning parameters with 16 unique settings, and
Table 2-2 shows 6 planning parameters with 23 unique settings. For this study, parameters were
varied independently to determine their individual effect on resulting plan quality, as varying all
combinations of parameters (almost 800,000 possibilities) together would be impractical using a
systematic approach.
2.2.3 Plan Evaluation
Plans from each trial were compared and evaluated using the dose volume histograms
(DVHs) calculated by Pinnacle, the dose homogeneity index (DHI) for each PTV, the conformity
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index (CI) for the primary PTVs of each treatment geometry, and the dose to normal tissue
metrics. The DHI was calculated as

DHI

$

D

max(1%)

D

# Dmin( 99%)

,

(1)

prescribed

where Dmin(99%) is the dose exceeded by 99% of the target volume and Dmax(1%) is the dose
exceeded by 1% of the target volume. This was done in order to avoid including artificially
high and low dose regions created by Pinnacle’s dose computation and/or small volumes of little
clinical interest. A perfectly homogenous dose to the PTV would result in a DHI of 0.0. The
conformity index (CI) was also used to evaluate the quality of each plan. The conformity index
measures how well the prescription dose conforms to the target volume, and it is defined as

CI
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where PIV is the volume covered by the prescribed isodose value, TV is the volume of the target,
and TVPIV is the volume of the target within the prescribed isodose value. Ideally the PIV, TV,
and TVPIV would be equal, making the CI equal to 1.
For the two cases involving normal tissue constraints (simple prostate and complex
prostate), normal tissue metrics were also used to evaluate the plan quality. “Hard” constraints
for normal tissues for intact prostate cancer treatment are described by Pollack et al. (2005):
!"#$%&'(%!)*$%+,%-./%0/1-&2%3+245/%0/1/63/7%89*:;%&'(%8<=:;>%0/7?/1-63/2;@%!A*$%&'(%!*=$%
of the bladder volume receives 89*:;%&'(%8<=:;>%0/7?/1-63/2;@%&'(%!"=$%+,%/&1.%,/5+0&2%./&(%
receives 8*=:;B%%C'/%+,%-./%&D7+24-/%1+'(6-6+'7%,+0%126'61&2%&11/?-&D626-;%+,%-./se prostate plans
was that 95% or greater of the PTV received 100% of the prescribed dose. For this reason, all
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prostate plans in our study were normalized so that 95% of the PTV received the prescription
dose. Normal tissue metrics were taken from Pollack et al., and evaluated at 17% and 35% of
the rectum, 25% and 50% of the bladder, and 10% of the femoral heads. The maximum dose to
the femoral heads were also evaluated, taken at Dmax(1%). The phantom case had no normal tissue
constraints, so only the DHI and CI were used in evaluating parameter trials for the phantom
case.
2.3 Specific Aims
Three treatment geometries of increasing complexity were chosen for this study in order
to determine the effect of varying both commissioning and planning parameters on resulting plan
quality. Each specific aim examined a single treatment geometry. The following sections
describe the details unique to each specific aim.
2.3.1 Specific Aim 1: Phantom Case
The first geometry, a phantom, was chosen to represent an ideal case for treatment.
Because it was important to start with the simplest conceivable case to determine an upper
threshold for the capabilities of SmartArc optimization, the phantom geometry can be described
as a simple approximation of a prostate PTV without any dose limiting structures. For the
phantom geometry, a spherical target was contoured in the center of a cylindrical, homogeneous,
water-equivalent phantom. The target was 7.5 inches in diameter, and it was centered inside the
30-inch diameter cylinder. A cylindrical phantom was chosen instead of a rectangular phantom
because it was believed to better represent the contour of the human body. The spherical target
was drawn using Pinnacle software in the center of the phantom, and there were no avoidance
structures identified. The prescription given to the phantom target for optimization was 200 cGy
to 95% of the PTV in 1 fraction, which represents a typical fractional dose for prostate cancer at
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our treatment facility. Because the tabular DVHs calculated by Pinnacle show dose in cGy, the
phantom plans were later prescribed 7600 cGy in 38 fractions to achieve a better dose resolution
for gathering data from the DVHs. Changing the number of fractions in the prescription did not
change the fractional DVH; all data points were merely multiplied by a factor of 38. A
transverse view of the phantom geometry is shown in Figure 2-2.

Figure 2-2. Transverse view of phantom
case. PTV is shown in red.
2.3.2 Specific Aim 2: Simple Prostate Case
The second geometry was a single-target prostate patient. This case was chosen because
it represented a relatively standard, simple prostate case. The patient selected had previously
been treated at our facility with fixed-beam, 7-field step-and-shoot IMRT. The original
prescription was 7600 cGy to the PTV in 38 fractions delivered with a 6MV beam, and
avoidance structures included the rectum, bladder, and left and right femoral heads. The
prescription for this study was kept the same as the original prescription. Transverse, sagittal,
and coronal views of the simple prostate geometry are shown in Figure 2-3.
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Figure 2-3. Transverse (top), sagittal (left), and coronal (right) view of simple prostate
case. PTV is shown in red.
2.3.3 Specific Aim 3: Complex Prostate Case
The third geometry used in this study was a complex prostate case with multiple PTVs.
This treatment site was chosen to represent a more complicated geometry. The patient was
previously treated at our facility with helical tomotherapy. The original prescription was 56 Gy
in 28 fractions to the extended prostate bed with a 22 Gy boost to the prostate bed; 61.6 Gy in 28
fractions to a positive node; and 46.2 Gy in 28 fractions to the entire nodal region. Avoidance
structures included the rectum, bladder, and left and right femoral heads. The prescription for
the SmartArc optimization was 78 Gy to the prostate bed (PTV 1), 61.6 Gy to the positive node
(PTV 2), 56 Gy to the extended prostate region (PTV 3), and 46.2 Gy to the extended nodal
region (PTV 4) in 28 fractions. Transverse, sagittal, and coronal views of the complex prostate
treatment geometry are shown in Figure 2-4.
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Figure 2-4. Transverse (top), sagittal (left), and coronal (right) views of complex
prostate geometry. PTV1: red, PTV2: green, PTV3: blue, PTV4: orange.
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3 RESULTS
This chapter describes the resulting plans based on metrics taken from the dose volume
histograms (DVHs), dose homogeneity indices (DHI), conformity indices (CI), and normal tissue
metrics. The results for the three baseline plans are described first, and then data for each
commissioning and planning parameter is presented simultaneously for all three specific aims.
3.1 Baseline Results
3.1.1 Phantom Baseline Results
A baseline plan was created to achieve acceptable dose homogeneity to the target for the
phantom case. A transverse image of the baseline plan is shown in Figure 3-1, where the red
shaded area represents the PTV. The corresponding DVH for the phantom baseline plan is
shown in Figure 3-2. A single, 360-degree dynamic arc beam with energy 6MV was used for the
baseline plan, and the isocenter for this beam was placed in the center of the target volume. The
plan was allowed 35 iterations, but a solution was found in only 21 iterations. The convolution
dose calculation started at iteration 8. The only optimization objectives set for this aim, listed in
Table 3-1, were maximum and minimum dose to the PTV. The prescription isodose line
(7600cGy) is shown in Figure 3-1, along with the prescription ±3% isodose lines (7372cGy and
7828cGy). All baseline commissioning and planning parameter values were discussed
previously and are shown in Table 2-3. All trials were normalized so that at least 95% of the
PTV received 100% of the prescribed dose. The optimization took approximately 15 minutes for
each trial (excluding smaller arc lengths) for the phantom case, and final dose computation took
about 20 minutes to complete for each trial.
Table 3-1. Optimization objectives for phantom case, Aim 1
ROI
PTV

Type
Max Dose

Target cGy
205

Weight
10

PTV

Min Dose

195

10
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Figure 3-1. Phantom baseline plan isodose lines (blue: 97%,
yellow: 100%, green: 103% of prescribed dose)

Figure 3-2. DVH for the phantom baseline plan. PTV:
red, no avoidance structures.
3.1.2 Simple Prostate Baseline Results
A baseline plan was created to achieve ±5% dose homogeneity to the simple prostate
target. A single, 360-degree dynamic arc beam with an energy of 6MV was used for the baseline
plan, and the isocenter for this beam was placed in the center of the prostate PTV. The
optimization was allowed 45 iterations, with the convolution dose calculation starting at iteration
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8. Figure 3-3 shows a transverse slice of the baseline plan for the simple prostate patient
including isodose lines for the prescription dose (7600cGy) and ± 5% of the prescription dose
(7372cGy and 7828cGy). Optimization objectives for the simple prostate case were kept very
similar to the optimization objectives of the original plan with only minor tuning in order to
reach homogeneity goals. A complete list of optimization objectives for the simple prostate case
Table 3-2. Optimization objectives for simple prostate case, Aim 2
ROI
PTV 76
PTV 76
PTV 76
76 only
Ring
Rectum
Rectum
Rectum
Bladder
Bladder
LFH
RFH

Type
Max dose
Min dose
Min DVH
Max dose
Max dose
Max DVH
Max DVH
Max DVH
Max DVH
Max DVH
Max dose
Max dose

Target cGy
7800
7300
7600
7600
3800
3500
7000
6500
4000
6000
4300
4300

% Volume
95
45
8
15
45
20
-

Figure 3-3. Simple prostate baseline plan isodose lines
(blue: 95%, yellow: 100%, green: 105% of prescribed
dose)
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Weight
10
10
45
1
1
1
1
1
1
1
1
1

Figure 3-4. DVH for the simple prostate baseline plan.
PTV: red, rectum: brown, bladder: yellow, right femoral
head: purple, left femoral head: blue.
is given in Table 3-2. All baseline commissioning and planning parameter values for the simple
prostate case were discussed previously and are shown in Table 2-3. After the baseline plan was
created, the DVH for the plan, shown if Figure 3-4, was approved by a radiation oncologist. It
was determined that the baseline plan was clinically acceptable for treatment based on dose
homogeneity to the target volume and normal tissue constraints. All trials were normalized so
that at least 95% of the PTV received 100% of the prescribed dose. The optimization took
approximately 40 minutes for each simple prostate trial (excluding smaller arc lengths), and final
dose computation took roughly 50 minutes to complete for each trial.
3.1.3 Complex Prostate Baseline Results
A baseline plan was created for the complex prostate case, attempting to achieve ±5%
dose homogeneity to the primary PTV. This homogeneity goal was not achieved, and the better
of two possible baseline plans was chosen by a radiation oncologist. Figure 3-5A and 3-5B show
transverse and saggital views of the patient where all 4 PTVs are visible. The prostate bed
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Table 3-3. Optimization objectives for complex prostate case, Aim 3
ROI
PTV 78
PTV 78
PTV 78
7800 ring
PTV 6160
6160 ring
PTV 56
5600 only
PTV 4620
4620 only
Ring 1
Rectum
Rectum
Bladder
Bladder
LFH
RFH

Type
Max Dose
Min Dose
Uniform Dose
Max Dose
Uniform Dose
Max Dose
Min DVH
Uniform Dose
Min DVH
Uniform Dose
Max Dose
Max DVH
Max DVH
Max DVH
Max DVH
Max Dose
Max Dose

Target cGy
7900
7600
7800
7800
6160
6160
5600
5600
4620
4620
3500
6500
4000
6500
4000
4200
4200

A

% Volume
95
95
17
35
25
50
-

Weight
100
100
100
1
75
1
1
1
30
25
1
20
30
20
20
40
40

B

Figure 3-5. Complex prostate baseline plan transverse (A) and sagittal (B) views.
Shaded areas represent PTVs, and corresponding lines represent 100% of the
prescribed dose for each PTV. PTV1 (7800cGy): red, PTV2 (6160cGy): blue, PTV3
(5600cGy): green, PTV4 (4620cGy): orange.
is shown in red (PTV 1; 7800 cGy), the extended prostate shown in dark blue (PTV 3; 5600
cGy), the positive node in purple (PTV 2; 6160 cGy), and the extended nodal region in light blue
(PTV 4; 4620 cGy). Figure 3-6 shows the DVHs for all PTVs and critical structures for the
complex prostate case. A single, 360-degree dynamic arc beam with energy 6MV was used for
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the baseline plan, and the isocenter was placed in the center of the composite target volumes.
The plan was allowed 35 iterations, with the convolution dose starting at iteration 10.
Optimization objectives for the complex prostate case baseline plan are shown in Table 3-3.
Because the patient was previously treated with helical tomotherapy, there was no previous set of
optimization objectives for the Pinnacle treatment planning system. Optimization objectives and

A regions of interest (such as rings) B
additional
were created to achieve a clinically acceptable
baseline plan. The baseline plan for the multi-target prostate case was determined to be
clinically acceptable by a radiation oncologist, though the "hard" normal tissue constraints
described by Pollack et al., for the most part, were not met. The baseline set of parameters was
identical to the single-target prostate case. Baseline commissioning and planning parameters are
shown in Table 2-3.
All trials were normalized so that at least 95% of the PTV received 100% of the
prescribed dose. The optimization took approximately 45 minutes for each complex prostate

Figure 3-6. DVH for the complex prostate baseline plan.
PTV1: red, PTV2: dark blue, PTV3: green, PTV4: orange,
rectum: brown, bladder: yellow, right femoral head: purple,
left femoral head: light blue.
31

trial (excluding smaller arc lengths), and final dose computation took roughly 80 minutes to
complete for each trial.
3.1.4 Baseline DHI and CI Values
Values of DHI , CI, and normal tissue metrics for the baseline plans are shown in Tables
3-1 to 3-3. DHI was lowest for the phantom case and highest for the PTVs of the complex
prostate case. CI was highest for the simple prostate case and lowest for the complex prostate
case. It is believed that CI performed better for the simple prostate case than the phantom case
because the phantom case had no avoidance structures. Normal tissue sparing was better for the
simple prostate case than the complex prostate case.
Table 3-4. Baseline values for DHI, Dmax, and Dmin for PTVs of the three treatment
geometries, shown in cGy.
Geometry (Dose Rx to 95% PTV)
Phantom (76 Gy)
Simple Prostate (76 Gy)
PTV 1 (78 Gy)
PTV 2 (61.6 Gy)
PTV 3 (56 Gy)
PTV 4 (46.2 Gy)

PTV Dmin(99%)
7540
7447
7481
6133
5333
4047

PTV Dmax(1%)
7812
8006
8744
6918
8721
7456

DHI
0.0358
0.0736
0.1619
0.1274
0.6050
0.7379

Table 3-5. Baseline values for CI for the three treatment geometries.
Geometry
Phantom
Simple Prostate
Complex Prostate (PTV1)

CI
0.8777
0.9106
0.7900

Table 3-6. Baseline values for normal tissue metrics for prostate geometries, shown in cGy.
Geometry

Rectum

Bladder

Rt. Fem. Head

Lt. Fem. Head

D17

D35

D25

D50

D10

Dmax(1%)

D10

Dmax(1%)

Simple Prostate

5297

3893

4420

1927

3702

3927

3855

4248

Complex Prostate

6666

5066

6054

4811

4250

4748

4477

4868

Pollack et al. (2008) limit 6500

4000

6500

4000

5000

--

5000

--
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3.2 Commissioning Parameters
3.2.1 Gantry Speed Variability
DHI, CI, and normal tissue values for gantry speed variability are shown in Tables 3-4
and 3-5. The DHI showed no change for the phantom and complex prostate cases and varied less
than 2% for the simple prostate case. In fact, the phantom and complex prostate cases showed
identical plans for both trials, and the simple prostate case showed little difference in the
resulting plans.
The CI showed no change for the phantom and complex prostate cases and differed by
less than 0.03 between trials for the simple prostate case.
Table 3-7. DHI and CI values for Gantry Speed Variability (PTV 1: 78Gy, PTV 2:
61.6Gy, PTV 3: 56Gy, PTV 4: 46.2Gy).
Dose Homogeneity Index
Phantom Simple Prostate

Gantry Speed
Variable (max 6 deg/sec)
not variable (6 deg/sec)

0.0358
0.0358

0.0736
0.0866

Conformity Index
Gantry Speed
Phantom Simple Prostate
Variable (max 6 deg/sec)
0.8777
0.9106
not variable (6 deg/sec)
0.8777
0.8956

PTV 1
0.1619
0.1619

Complex Prostate
PTV 2
PTV 3
0.1274
0.6050
0.1274
0.6050

PTV 4
0.7379
0.7379

Complex Prostate
0.7900
0.7900

Table 3-8. Normal tissue metrics for Gantry Speed variation for simple and complex
prostate cases. All normal tissue dose metrics are shown in cGy.
Rectum
D17
D35

Gantry
Speed

Norm.
%

variable
not variable

95.4
95.4

5297
5371

3893
3955

variable
not variable

95
95

6666
6666

5066
5066

Bladder
Rt. Femoral Head
D25
D50
D10
Dmax(1%)
Simple Prostate
4420 1927
3702
3927
4458 1906
3767
4023
Complex Prostate
6054 4811
4250
4748
6054 4811
4250
4748
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Lt. Femoral Head
D10
Dmax(1%)
3855
3820

4248
4209

4477
4477

4868
4868

Absolute dose values for normal tissue metrics for the two prostate cases are shown in
Table 3-5. Normal tissue metrics were within 3% of the baseline values for the simple prostate
case, and did not change for the complex prostate case. Resulting plans showed no significant
dependence on allowing the gantry speed to vary during treatment.
3.2.2 Maximum Gantry Speed
The maximum gantry speed was varied above and below that of the baseline plan (6
deg/sec) to determine if a faster or slower rotation speed would improve or degrade the plan
quality. The resulting DHI and CI are graphed in Figures 3-7 to 3-9.
Figure 3-7 shows that DHI values for the phantom were the lowest, and DHI values for
the complex prostate PTV 1 were highest. This was the case for all parameters studied. The
DHI for the phantom and simple prostate cases varied by less than 0.02 as the maximum gantry
speed increased from 4 deg/sec to 12 deg/sec. The variation in DHI for the baseline trial and
DHI for 12 deg/sec trial for PTV1 was 0.026, and the 12 deg/sec trial performed best.

Figure 3-7. DHI for “Maximum Gantry Speed” parameter:
phantom (green), simple prostate (red), and PTV 1 (blue) of
complex prostate case.
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Figure 3-8. DHI for “Maximum Gantry Speed” parameter:
PTV 1 (blue), PTV 2 (red), PTV 3 (green), and PTV 4 (purple) of
complex prostate case.
The data in Figure 3-8 shows that the DHI values for PTV 3 and PTV 4 were much
greater than the DHI values for PTV 1 and PTV 2. This indicates that the dose to PTV 3 and
PTV 4 was less homogeneous than the dose to PTV 1 and PTV 2.
Resulting CI values are plotted for varying maximum gantry speed in Figure 3-9. The
variation in CI values across all maximum gantry speeds for the phantom and simple prostate

Figure 3-9.CI for “Maximum Gantry Speed” parameter:
phantom (green), simple prostate (red), and complex prostate
(blue) cases.
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cases was less than 0.02. The variation in CI values between the baseline trial and 12 deg/sec
trial for the complex prostate case was 0.044, improving as the maximum gantry speed
increased.
Normal tissue metrics for variation of maximum gantry speed are plotted in Figure 3-10
for the two prostate cases. The normalized dose is plotted against the maximum gantry speed for
all normal tissue metrics. The two dotted lines represent 2% above and below the baseline dose

Figure 3-10. Normal tissue metrics for “Maximum Gantry Speed” parameter for simple
prostate and complex prostate cases. All doses normalized to dose values for the baseline
trial (6deg/sec).
value. Dose values for all metrics were normalized to those of the baseline plan; therefore, all
plots intersect at 6 deg/sec, the baseline setting for this parameter. It is evident from the simple
prostate graph that all variations for normal tissue dose metrics were within 2% of the baseline
dose value. The complex prostate normal tissue metrics varied more than 2% for some normal
tissue metrics, but generally improved (lower dose) as the maximum allowable gantry speed
increased.
3.2.3 Maximum Dose Rate
Figures 3-11 and 3-12 show DHI values plotted for the phantom case, simple prostate
case, and complex prostate case. Both continuously variable dose rates (circles) and discretely
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Figure 3-11. DHI for “Maximum Dose Rate” parameter:
phantom (green), simple prostate (red), and PTV 1 (blue) of
complex prostate case.

Figure 3-12. DHI for “Maximum Dose Rate” parameter: PTV 1
(78 Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, green), and
PTV 4 (46.2 Gy, purple) of complex prostate case.
variable dose rates (triangles) are plotted for all PTVs. As the maximum dose rate increased
from 400 MU/min to 800 MU/min, the DHI values for the phantom, simple prostate, and
PTV1of the complex prostate varied by less than 0.02 for both continuously variable and
discretely variable dose rates. Figure 3-12 shows DHI values for all PTVs of the complex
prostate case. The DHI values for PTV2 for 400 MU/min differed by 0.052 and 0.023 from the
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baseline DHI value (at 600 MU/min max) for discretely and continuously variable dose rates,
respectively. The DHI values for PTV3 varied by 0.026 and 0.039 for discretely and
continuously variable dose rates, respectively. The DHI for PTV4 varied by 0.042 and 0.029 for
discretely and continuously variable dose rates, respectively. For all maximum dose rates and all
treatment sites shown, the DHI for the continuously variable dose rates differed from the DHI for
the discretely variable dose rates by less than 0.025. Only the DHI for PTV2 and PTV3 differed
by more than 0.02 between continuous and discretely variable dose rates for the 600 MU/min
maximum dose rate trials.
CI values for all maximum dose rates and all treatment sites are shown in Figure 3-13.
CI for the phantom, simple prostate, and complex prostate cases varied by less than 0.02 over all
maximum dose rates, both continuously and discretely variable. For all maximum dose rates and

Figure 3-13. CI for “Maximum Dose Rate” parameter: phantom
(green), simple prostate (red), and complex prostate (blue)cases.
all treatment sites shown, the CI for the continuously variable dose rates differed from the CI for
the discretely variable dose rates by less than 0.02.

38

Normal tissue metrics for maximum dose rate variation are shown in Table 3-9. Dose
values for all trials were normalized to the baseline plan. For a given maximum dose rate, the
difference in dose values between continuously variable dose rates and discretely variable dose
rates was less than 3% for most metrics across both treatment sites. The variation in dose to
normal tissue metrics for changing maximum dose rates, however, was greater than 3% for
every metric for the simple prostate case except for D25 of the bladder. For the complex prostate
case, only D50 for the bladder (800 continuous) and D10 for the right femoral head (400 discrete)
had greater than a 3% variation from the baseline value.

Table 3-9. Normal tissue metrics for Dose Rate variations for simple and complex
prostate cases. All normal tissue dose metrics are normalized to baseline values.
Maximum
Dose Rate
400 Disc*
400 Cont*
600 Disc
600 Cont
800 Disc
800 Cont

Norm
%
95.7
95.4
95.4
95.3
95.7
95.5

Rectum
D17
D35
1.053
1.053
1.000
1.024
0.996
0.999

1.058
1.052
1.000
1.019
0.967
0.980

Bladder
Rt. Femoral Head
D25
D50
D10
Dmax(1%)
Simple Prostate
1.021 1.033
0.897
0.922
1.024 1.052
0.907
0.930
1.000 1.000
1.000
1.000
1.015 1.031
0.985
0.982
1.003 1.002
1.108
1.095
1.013 1.029
1.031
1.036

Complex Prostate
400 Disc
95
1.014 1.016 0.995 1.015
1.031
0.999
400 Cont
95.3
1.020 1.022 1.010 1.018
1.028
1.007
600 Disc
95
1.000 1.000 1.000 1.000
1.000
1.000
600 Cont
95.3
0.997 0.991 0.996 0.989
0.986
0.976
1.002
0.979
800 Disc
94.9
1.006 1.027 1.026 0.996
1.016
0.988
800 Cont
94.9
1.009 1.005 0.773 1.230
* Disc = discretely variable dose rate, Cont = continuously variable dose rate

Lt. Femoral Head
D10
Dmax(1%)
0.971
0.948
1.000
0.955
0.914
0.930

0.997
0.979
1.000
0.972
0.944
0.951

1.012
1.000
1.000
0.996
0.991
1.002

0.997
0.987
1.000
0.983
0.996
0.986

3.2.4 Maximum MLC Leaf Speed
Figures3-14and 3-15 show the effect of varying maximum leaf speed on DHI for the
phantom, simple prostate, and complex prostate cases. As the maximum leaf speed was
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Figure 3-14. DHI for “Maximum MLC Leaf Speed”
parameter: phantom (green), simple prostate (red),
and PTV 1 (blue) of complex prostate case.

Figure 3-15. DHI for “Maximum MLC Leaf Speed”
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy,
red), PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy,
purple) of complex prostate case.
increased, the DHI for the phantom and simple prostate cases showed less than 0.02 variation
while PTV 1 of the complex prostate case showed a variation of 0.025 in DHI values between
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2cm/sec and 3cm/sec maximum leaf speed. DHI for PTV 1, PTV 2, and PTV 4 varied by 0.025,
0.085 and 0.128, respectively, and generally improved as maximum leaf speed increased. The
DHI for PTV 3 varied by less than 0.02 among all maximum leaf speeds.
CI for maximum leaf speed variation is plotted in Figure 3-16. For the phantom and
simple prostate cases, the CI varied by less than 0.02 across all maximum leaf speeds. For the
complex prostate case, the CI variation was 0.022, and the CI improved as maximum leaf speed
increased.

Figure 3-16. CI for “Maximum MLC Leaf Speed”
parameter: phantom (green), simple prostate (red), and
complex prostate (blue) cases.
Normal tissue metrics for changing maximum MLC leaf speed are shown in Table3-10.
All dose values are normalized to the baseline trial. For the simple prostate case, metrics that
exceeded a 3% variation in dose across all trials were D17 for the rectum, D25 for the bladder, and
all metrics for the femoral heads. Metrics that exceeded 3% variation for the complex prostate
case were D17 for the rectum, both bladder metrics, and all metrics for the femoral heads except
for Dmax(1%) for the right femoral head. With only 2 exceptions, metrics for the rectum and
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bladder performed worse than the baseline plan for both 1 cm/sec and 3 cm/sec trials, while
metrics for the femoral heads performed better.
Table 3-10. Normal tissue metrics for Maximum MLC Leaf Speed variations for simple
and complex prostate cases. All normal tissue dose metrics are normalized to baseline
values.
Max MLC Norm
Leaf Speed
%

Rectum
D17
D35

1 cm/sec
2 cm/sec
3 cm/sec

95.9
95.4
95.9

1.031
1.000
1.027

1.022
1.000
1.016

1 cm/sec
2 cm/sec
3 cm/sec

95.3
95
95

1.030
1.000
0.995

1.029
1.000
0.999

Bladder
Rt. Femoral Head
D25
D50
D10
Dmax(1%)
Simple Prostate
1.085 1.007
0.937
0.945
1.000 1.000
1.000
1.000
1.050 1.030
0.994
0.982
Complex Prostate
1.073 1.066
1.007
0.985
1.000 1.000
1.000
1.000
1.014 1.006
0.951
0.994

Lt. Femoral Head
D10
Dmax(1%)
0.963
1.000
0.961

0.958
1.000
0.972

0.975
1.000
0.965

0.955
1.000
0.942

3.2.5 MLC Leaf Size
DHI and CI results for varying MLC size are shown in Table 3-11. DHI values for the
two leaf sizes for the phantom and simple prostate cases differed by less than 0.02. The variation
in DHI for PTV1, PTV2, and PTV4 of the complex prostate case was also less than 0.02, while
the DHI value for PTV3 was 0.043 lower for 1cm leaf size.
The difference in CI values for the two leaf sizes for phantom and simple prostate cases
was less than 0.02. The CI value for PTV1 was 0.03 greater for the 5mm leaf size.
Table 3-11. DHI and CI values for MLC Leaf Size (PTV 1: 78Gy, PTV 2:
61.6Gy, PTV 3: 56Gy, PTV 4: 46.2Gy).
Dose Homogeneity Index
Leaf Size Phantom Simple Prostate
1 cm
5mm

0.0358
0.0426

Conformity Index
Leaf Size Phantom
1 cm
0.8777
5mm
0.8634

0.0736
0.0768

Simple Prostate
0.9106
0.8946
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Complex Prostate
PTV 1
PTV 2 PTV 3
0.1619
0.1274 0.6050
0.1473
0.1068 0.6482

Complex Prostate
0.7900
0.8196

PTV 4
0.7379
0.7091

Normal tissue metrics for the different MLC leaf sizes are shown in Table 3-12. For the
simple prostate case, dose metrics for the rectum and D25 for the bladder were less than 3%
Table 3-12. Normal tissue metrics for MLC Leaf Size variation for simple and
complex prostate cases. All normal tissue dose metrics are shown in cGy.
Rectum

Leaf
Size

Norm
%

D17

D35

1 cm
5 mm

95.4
95.6

3893
4014

4420
4541

1 cm
5 mm

95
94.8

6666
6627

5066
4960

Bladder

Rt. Femoral Head

D25
D50
D10
Simple Prostate
1927
3702
3927
1965
3373
3800
Complex Prostate
6054
4811
4250
5810
4543
3937

Lt. Femoral Head

Dmax(1%)

D10

Dmax(1%)

3855
3476

4248
3815

4248
4147

4748
4383

4477
4239

4868
4628

different between the two trials. All other metrics differed by up to 10% and performed better
for the 5mm leaf size. For the complex prostate case, all metrics differed by more than 3%
between the two trials except for D17 of the rectum. The greatest discrepancy was about 8% for
both metrics for the right femoral head. Dose metrics for the complex prostate case performed
better for the 5mm leaf size trial.
3.2.6 Maximum MU/degree
Two trials were run to investigate the effect of changing the maximum MU/degree: 100
MU/deg and 1 MU/deg. DHI and CI results are shown in Table 3-13. Phantom and complex
Table 3-13. DHI and CI values for Maximum MU/degree (PTV 1: 78Gy,
PTV 2: 61.6Gy, PTV 3: 56Gy, PTV 4: 46.2Gy).
Dose Homogeneity Index
MU/degree

Phantom

Simple Prostate

100 MU/deg
1 MU/deg

0.0358
0.0358

0.0736
0.0728

Conformity Index
MU/degree Phantom
100 MU/deg
0.8777
1 MU/deg
0.8777

Simple Prostate
0.9106
0.9127
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Complex Prostate
PTV 1
PTV 2 PTV 3
0.1619
0.1274 0.6050
0.1619
0.1274 0.6050

Complex Prostate
0.7900
0.7900

PTV 4
0.7379
0.7379

prostate cases showed identical resulting plans for this parameter, and the simple prostate case
varied less than 0.02 for both DHI and CI. Allowing only 1 MU/degree would result in a plan
with a maximum of 360 MU for a 360 degree total arc length. All resulting plans for 1MU/deg
trials exceeded 360 MU. The control point data was reviewed for these trials, and hand
calculations for MU/degree verified that the treatment planning system ignored the 1 MU/deg
limitation.
Normal tissue metrics for MU/degree trials are shown in Table 3-14. Values for the
simple prostate case varied less than 3% between trials.

Table 3-14.Normal tissue metrics for Maximum MU/degree variations for simple and
complex prostate cases. All dose values are shown in cGy.
MU/degree

Rectum

Norm.
%

D17

D35

Bladder
D35

D50

Rt. Femoral Head

Lt. Femoral Head

D10

Dmax(1%)

D10

Dmax(1%)

3702
3647

3927
3877

3855
3760

4248
4147

4250
4250

4748
4748

4477
4477

4868
4868

Simple Prostate
100 MU/deg
1 MU/deg

95.4
95.5

5297
5381

3893
3930

4420
4405

1927
1963

Complex Prostate
100 MU/deg
1 MU/deg

95
95

6666
6666

5066
5066

6054
6054

4811
4811

3.3 Planning Parameters
3.3.1 Beam Energy
Figures 3-17 and 3-18 are plots of the resulting DHI for energies of 6MV, 10MV, and
15MV. DHI values for the phantom and simple prostate cases varied by less than 0.02 for all
three energies. The difference in DHI for PTV1 between the 6MV trial and the 15MV trial was
0.038, and the DHI performed better for lower energies. The differences in DHI for PTV2,
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Figure 3-17. DHI for “Beam Energy” parameter: phantom
(green), simple prostate (red), and PTV 1 (blue) of complex
prostate case.

Figure 3-18. DHI for “Beam Energy” parameter: PTV 1 (78
Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, green), and
PTV 4 (46.2 Gy, purple) of complex prostate case.
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PTV3, and PTV4 (between the baseline DHI value and the DHI value with greatest variation
from the baseline value) were 0.028, 0.038, and 0.071, respectively, and there was no consistent
trend for DHI performance as beam energy increased.
The CI for all treatment sites and all energies is shown in Figure 3-19. The variation in
CI across the three beam energies was 0.056, 0.022, and 0.07 for the phantom case, the simple
prostate case, and the complex prostate case, respectively. There was no common trend for
target conformity as beam energy increased.

Figure 3-19. CI for “Beam Energy” parameter: phantom
(green), simple prostate (red), and complex prostate (blue)
cases.
Table 3-18. Normal tissue metrics for Beam Energy variations for simple and complex
prostate cases. All normal tissue dose metrics are normalized to baseline values.
Rectum
D17
D35

Beam
Energy

Norm.
%

6 MV
10 MV
15 MV

95.4
96.1
96.2

1.000
0.986
1.026

1.000
0.915
1.000

6 MV
10 MV
15 MV

95
95.2
95.2

1.000
1.000
1.011

1.000
1.017
1.035

Bladder
Rt. Femoral Head
D25
D50
D10
Dmax(1%)
Simple Prostate
1.000 1.000 1.000
1.000
1.036 1.020 1.078
1.091
1.042 1.118 1.007
1.028
Complex Prostate
1.000 1.000 1.000
1.000
1.019 1.016 1.058
1.045
1.008 0.995 1.120
1.060
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Lt. Femoral Head
D10
Dmax(1%)
1.000
1.038
1.011

1.000
1.034
1.014

1.000
0.987
1.017

1.000
0.978
1.016

Normal tissue metrics for the three beam energies are shown in Table 3-18 for the simple
and complex prostate cases, normalized to the baseline plan. With few exceptions, the higher
energies performed worse for sparing normal tissue, and most metrics had greater than 3%
variation across all energies for both treatment sites.
3.3.2 Arc Length
DHI for varying arc lengths are shown in Figure 3-20 for the phantom, simple prostate,
and PTV1 of the complex prostate. DHI for varying arc lengths are shown in Figure 3-21 for all
PTVs of the complex prostate case. The DHI improved as the arc length increased for all PTVs.
The larger arc lengths involved more control points, which allowed for better modulation of the
dose to the target volume. Pinnacle version 8.1y does not have double arc optimization
capabilities,so 360 deg was the largest arc studied here. From 60 to 180 degrees total arc length,
there is an extreme improvement in DHI as arc length is increased. Between 180 degrees and
360 degrees total arc length, DHI continues to improve, but the rate of improvement is not as
severe. This is due to exit dose generated by the photon radiation. The entire PTV is treated
with a 180-degree arc, but a 360-degree arc allows for improvement in dose homogeneity.

Figure 3-20. DHI for “Arc Length” parameter: phantom
(green), simple prostate (red), and PTV 1 (blue) of
complex prostate case.
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Figure 3-21. DHI for “Arc Length” parameter: PTV 1
(78 Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy,
green), and PTV 4 (46.2 Gy, purple) of complex prostate
case.
The CI for arc length trials are plotted in Figure 3-22. As expected, the CI also improved
as arc length increased because more control points allowed for better conformity of the
prescription dose to the PTV. The rate of improvement in CI also declined at 180 degrees total
arc length.
Normal tissue metrics for arc length variations are shown in Figure 3-23. For the smaller
arc lengths, normal tissue sparing depended greatly on how the arc was oriented. With the

Figure 3-22. CI for “Arc Length” parameter: phantom
(green), simple prostate (red), and complex prostate
(blue) cases.
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exception of the femoral heads, which were partly spared for smaller arcs, normal tissue sparing
improved as arc length increased.

Figure 3-23.Normal tissue metrics for “Arc Length” parameter for simple prostate and
complex prostate cases. All doses normalized to dose values for the baseline trial (360 deg).

3.3.3 Collimator Angle
The collimator angle was varied from 0 to 90 degrees for all treatment sites. For the
phantom case, the baseline collimator angle was 90 degrees. For both the simple and complex
prostate cases, the baseline collimator angle was 0 degrees. Figures 3-24 and 3-25 show the DHI
values for all three treatment sites for all collimator angles studied. The DHI variation across all
collimator angles for the phantom case was less than 0.02. The greatest variation in DHI values
all collimator angles for the simple prostate case was 0.027. For the complex prostate case,
changing collimator angle had the biggest effect on the DHI for PTV4, where DHI values varied
by 0.294 from a collimator angle of 0 degrees to a collimator angle of 90 degrees. PTV1, PTV2,
and PTV3 had DHI variations of 0.047, 0.061, and 0.062, respectively.
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Figure 3-24. DHI for “Collimator Angle” parameter:
phantom (green), simple prostate (red), and PTV 1 (blue) of
complex prostate case.

Figure 3-25. DHI for “Collimator Angle” parameter: PTV 1
(78 Gy, blue), PTV 2 (61.6 Gy, red), PTV 3 (56 Gy, green), and
PTV 4 (46.2 Gy, purple) of complex prostate case.
CI for collimator angle variations are shown in Figure 3-26. The CI values for the
phantom and the simple prostate cases varied across all collimator angles by 0.059 and 0.069,
respectively. The largest variation in CI values was 0.127 for the PTV1 of the complex prostate
case.
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Figure 3-26. CI for “Collimator Angle” parameter:
phantom (green), simple prostate (red), and complex
prostate (blue) cases.
Normal tissue metrics for the simple and complex prostate cases are plotted against
collimator angle in Figure 3-27. Metrics for the simple prostate case generally varied more than
metrics for the complex prostate case. The simple prostate case had fewer optimization goals
and constraints than the complex prostate case, allowing the optimization more room to diverge
from the baseline plan. For the simple prostate case, D50 for the bladder varied over 40% by
changing the collimator from 0 degrees to 90 degrees. All other metrics, except for the left
femoral head varied between 17% and 25% from 0 to 90 degrees. The most variation from the

Figure 3-27. Normal tissue metrics for “Collimator Angle” parameter for simple prostate
and complex prostate cases. All doses normalized to dose values for the baseline trial (360
deg).
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baseline plan for the complex prostate case was 12% for D25 for the bladder with a collimator
angle of 60 degrees.
3.3.4 Dose Grid Resolution
Trials were run for 0.3cm, 0.4cm, and 0.5cm resolution. Figures 3-28 and 3-29 show
DHI values for the phantom, simple prostate, and complex prostate cases. For the complex
prostate case, only dose grid resolutions of 0.4cm and 0.5cm were used due to software failures

Figure 3-28. DHI for “Dose Grid Resolution”
parameter: phantom (green), simple prostate (red), and
PTV 1 (blue) of complex prostate case.

Figure 3-29. DHI for “Dose Grid Resolution”
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, red),
PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, purple) of
complex prostate case.
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of the treatment planning system. The variation in DHI values across all dose grid resolutions
for the phantom case was less than 0.02. The variation in DHI values for the simple prostate
case was only 0.021. The difference in DHI values between both dose grid resolutions for PTV1
and PTV2 of the complex prostate case was less than 0.02, while the difference in DHI values
for PTV3 and PTV4 between both dose grid resolutions was 0.023 and 0.060, respectively.

Figure 30.CI for “Dose Grid Resolution” parameter:
phantom (green), simple prostate (red), and complex
prostate (blue) cases.
Table 3-19. Normal tissue metrics for Dose Grid Resolution variations for simple and
complex prostate cases. All normal tissue dose metrics are normalized to baseline
values (0.4cm).
Rectum
D17
D35

Dose Grid
Resolution

Norm
%

0.3 cm
0.4 cm
0.5 cm

95.3
95.4
95.4

0.970
1.000
1.054

0.968
1.000
1.062

0.4 cm
0.5 cm

95
95

1.000
1.013

1.000
1.001

Bladder
Rt. Femoral Head
D25
D50
D10
Dmax(1%)
Simple Prostate
1.034 1.070
0.928
0.979
1.000 1.000
1.000
1.000
1.056 1.061
0.940
1.015
Complex Prostate
1.000 1.000
1.000
1.000
1.036 1.013
0.930
0.933

Lt. Femoral Head
D10
Dmax(1%)
0.967
1.000
0.932

0.965
1.000
0.935

1.000
0.832

1.000
0.907

The CI for all treatment sites is plotted against the dose grid resolution in Figure 3-30.
The variation in CI values was 0.050 for the phantom case and 0.031for the simple prostate case.
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A dose grid resolution of 0.3cm provided the worst CI for both the phantom and simple prostate
cases. The two CI values for the complex prostate case differed by less than 0.02.
Normal tissue metrics for dose grid resolution variation are shown in Table 3-19,
normalized to the baseline values. All metrics for the simple prostate case and most metrics for
the complex prostate case showed greater than 3% variation from the baseline values. The dose
to both rectum metrics and to D50 of the bladder varied by less than 3% between the 0.5cm trial
and the baseline trial for the complex prostate case.
3.3.5 Final Gantry Spacing
The setting for final gantry spacing determines the spacing of control points around the
final arc. The options for final gantry spacing were 2, 3, 4, or 6 degrees. It is recommended in
the literature to start with a spacing of 4 degrees (RaySearch Laboratories, 2009). DHI values
are shown for all spacing options for all treatment sites in Figures 3-31 and 3-32. Trials with 2

Figure 3-31. DHI for “Final Gantry Spacing” parameter:
phantom (green), simple prostate (red), and PTV 1 (blue) of
complex prostate case.
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and 3 degrees final spacing could not be run for the complex prostate case due to software
failures of the treatment planning system. For the phantom case, the variation in DHI values
across all final gantry spacing options was less than 0.02. The variation in DHI values for the
simple prostate case was less than 0.02 for 2, 3, and 4 degrees final gantry spacing, but for 6
degree final gantry spacing, the DHI increased by 0.027 from the baseline value (4 degrees).
Similarly, the DHI value for 6 degree final gantry spacing for PTV1 of the complex prostate case
was 0.030 higher than the baseline, and the DHI value for 6 degree final gantry spacing for
PTV3 was 0.028. The difference in DHI values for PTV2 and PTV4 was less than 0.02 between
4 and 6 degrees final gantry spacing trials.

Figure 3-32. DHI for “Final Gantry Spacing”
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, red),
PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, purple) of
complex prostate case.
The CI values for final gantry spacing trials are shown in Figure 3-33. Similar to the DHI
plots, the variation in CI values for the phantom and simple prostate cases remained less than
0.02 for 2, 3, and 4 degree final gantry spacing. The difference in CI values between 4- degree
final gantry spacing and 6-degree final gantry spacing was 0.049 for the phantom case, 0.032 for
the simple prostate case, and 0.117 for the complex prostate case. Target conformity was worst
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Figure 3-33. CI for “Final Gantry Spacing” parameter:
phantom (green), simple prostate (red), and complex
prostate (blue) cases.
for 6 degree final gantry spacing for all treatment sites, most dramatically for the complex
prostate.
All normal tissue metrics for final gantry spacing variations are shown in Table 3-20,
normalized to the baseline values (4 degrees). For the simple prostate case, 6-degree final gantry
spacing, all metrics showed greater than 3% difference from the baseline plan except Dmax(!%) for
both femoral heads. The only other metrics that showed greater than 3% difference from the
Table 3-20. Normal tissue metrics for Final Gantry Spacing variations for simple and
complex prostate cases. All normal tissue dose metrics are normalized to baseline
values (4 deg).
Final
Gantry
Spacing

Norm
%

Rectum
D17

D35

2 deg
3 deg
4 deg
6 deg

95.9
95.5
95.4
95.2

0.993
1.003
1.000
1.061

0.965
0.978
1.000
1.048

4 deg
6 deg

95
95

1.000
1.031

1.000
1.064

Bladder
D25

D50

Rt. Femoral Head
D10

Simple Prostate
0.997
1.024
1.020
0.992
0.983
0.985
1.000
1.000
1.000
1.040
0.929
0.935
Complex Prostate
1.000
1.000
1.000
1.012
1.019
1.071
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Lt. Femoral Head

Dmax(1%)

D10

Dmax(!%)

1.022
0.997
1.000
0.980

1.005
0.981
1.000
0.955

1.034
1.009
1.000
0.997

1.000
1.016

1.000
1.023

1.000
0.999

baseline values for the simple prostate case were D35 of the rectum, and Dmax(!%) of the left
femoral head for 2 degree final gantry spacing. For the complex prostate case, 6 degree final
gantry spacing, both rectum metrics and D10 of the right femoral head showed greater than 3%
difference from the baseline values.
3.3.6 Maximum Delivery Time
The data collected in this study for maximum delivery time was based on the userrequested maximum delivery time, not the actual delivery time estimated by Pinnacle after
optimization. Table 3-21 shows both the input maximum delivery times (user-requested) and
estimated delivery times for the three treatment sites. Trials were run for all treatment sites with
60-second, 120-second, and 240-second maximum delivery times, along with intermediate
maximum delivery times that were different for each treatment geometry.
Table 3-21. Input maximum delivery time and estimated delivery time for all trials, all
treatment sites.

Input (sec)
20
45
60
-120
-240

Phantom
Est. Delivery (sec)
60
60
60
-98
-194

Simple Prostate
Input (sec) Est. Delivery (sec)
20
60
--60
60
90
88
120
110
--240
211

Complex Prostate
Input (sec) Est. Delivery (sec)
----60
64
--120
119
150
143
240
194

The data for DHI values for different maximum delivery times is shown in Figures 3-34
and 3-35. The phantom case resulted in identical plans for both 20-second maximum delivery
time and 45-second maximum delivery time. The actual estimated delivery time for both plans
was approximately 60 seconds, indicating that the 20-second and 45-second limitations were
rejected by the treatment planning system for those trials. The variation in DHI values for all
other trials for the phantom case were within 0.02 of the baseline DHI value (120 seconds). The
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variation in DHI values for the simple prostate case remained within 0.02 of the baseline DHI
values for 20-second, 60-second, and 90-second trials. The DHI value for the 240-second trial
for the simple prostate case, however, was 0.028 greater than the DHI for the baseline trial. For
the simple prostate case, the longest maximum delivery time requested resulted in worse dose
homogeneity across the PTV. DHI values for the 60-second and 150-second trials for PTV1 of
the complex prostate case were within 0.02 of the baseline DHI value, but the DHI value for the
240-second trial was 0.028 less than the baseline value. For PTV1 of the complex prostate case,

Figure 3-34. DHI for “Maximum Delivery Time”
parameter: phantom (green), simple prostate (red),
and PTV 1 (blue) of complex prostate case.

Figure 3-35. DHI for “Maximum Delivery Time”
parameter: PTV 1 (78 Gy, blue), PTV 2 (61.6 Gy, red),
PTV 3 (56 Gy, green), and PTV 4 (46.2 Gy, purple) of
complex prostate case.
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the longer maximum delivery time resulted in better dose homogeneity across the target volume.
DHI values for all PTVs of the complex prostate case are plotted in Figure 3-35. The DHI for
the 60-second trial for PTV2 differed by 0.028 from the baseline trial, while DHI values for all
other trials for PTV2 were within 0.02 of the baseline DHI value. For PTV3, the 150-second
trial resulted in a DHI value 0.032 greater than the baseline DHI value. DHI values for PTV4
were mostly within 0.02 variation from the baseline plan, but the DHI for the 60-second trial was
0.051greater.
The CI as a function of maximum delivery time is shown in Figure 3-36. All trials for
the phantom case resulted in a variation of CI values of less than 0.02 from the baseline CI value
(120 seconds). CI values for the simple prostate case were within 0.02 of the baseline value for
the 20-second, 60-second, and 90-second trials, but the CI value for the 240-second trial was
0.036 lower than the CI value for the baseline trial. All CI values for the complex prostate case
were within 0.02 of the baseline CI value.

Figure 3-36. CI for “Maximum Delivery Time”
parameter: phantom (green), simple prostate (red), and
complex prostate (blue) cases.
Normal tissue metrics for varying maximum delivery time are plotted in Figure3-37,
normalized to the baseline trial. For the simple prostate case, the right femoral head received
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greater dose as the maximum delivery time increased, but both rectum metrics received less dose
for greater maximum delivery times. The left femoral head showed no trend as requested
delivery timed increased, but performed worst for the baseline trial. The bladder metrics showed
no consistent trend, but were lowest for the baseline trial. For the complex prostate case, all
normal tissues generally performed better for longer maximum delivery times, with the
exception of the femoral heads.

Figure 3-37. Normal tissue metrics for “Maximum Delivery Time” parameter for simple
prostate and complex prostate cases. All doses normalized to dose values for the baseline
trial (120 sec).
3.4 Monitor Units and Delivery Time
Two of the most advertised advantages of VMAT treatments are monitor unit and time
efficiency. Table 3-22 shows the monitor units and estimated delivery time per fraction for each
trial and each treatment geometry in this study. In general, the phantom case required the fewest
MU and had the shortest fractional treatment times, while the the complex prostate case required
the most MU and had the longest fractional treatment times. The phantom case also showed the
least variation in MU and treatment times for any given parameter, while the complex prostate
showed the most.
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The original fixed-beam IMRT plan for the simple prostate patient required 719
MU/fraction. The estimated delivery time for this patient was between 8 and 11 minutes. The
baseline VMAT plan (with comparable plan quality) required 34% fewer MU and 77% less time
to deliver than the original IMRT plan for the simple prostate case. The complex prostate patient
was originally treated with tomotherapy and required MU is unknown.
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Table 3-22. MU and estimated delivery times for all parameters, trials, and treatment
sites. All baseline trials are shown in bold.
Parameter
Gantry speed variability
Maximum Gantry Speed

Maximum Dose Rate

Maximum MLC Leaf Speed

MLC size
Maximum MU/degree
Beam Energy

Arc Length

Collimator Angle

Dose Grid Resolution

Final Gantry spacing

Maximum Delivery Time

Trial
yes
no
6 deg/sec
4 deg/sec
8 deg/sec
12 deg/sec
Disc 600
Cont 600
Disc 400
Cont 400
Disc 800
Cont 800
2 cm/sec
3 cm/sec
1 cm/sec
1 cm
0.5 cm
100
MU/deg
1 MU/deg
6 MV
10 MV
15 MV
60 deg
120 deg
180 deg
270 deg
360 deg
0 deg
30 deg
45 deg
60 deg
90 deg
0.4 cm
0.3 cm
0.5 cm
4 deg
2 deg
3 deg
6 deg
120 sec
60 sec
240 sec

Phantom
Delivery
MU
Time
329
98
329
98
329
98
329
97
329
95
329
95
329
98
329
98
329
99
329
97
329
99
329
97
329
98
329
98
329
98
329
98
332
105

Simple Prostate
Delivery
MU
Time
478
110
474
114
478
110
479
110
477
109
476
109
478
110
474
113
455
117
461
120
488
110
482
106
478
110
469
112
439
107
478
110
449
99

Complex Prostate
Delivery
MU
Time
826
119
826
119
826
119
805
117
837
116
845
117
826
119
812
119
737
121
705
120
791
99
789
106
826
119
763
115
722
115
826
119
870
118

329

98

478

110

826

119

329
329
279
266
384
355
345
329
329
331
331
336
334
329
329
334
329
329
329
329
332
329
330
329

98
98
112
98
109
112
100
105
98
97
107
104
98
98
98
120
97
98
98
103
120
98
60
194

473
478
407
387
506
379
463
402
478
478
432
442
402
399
478
506
458
478
493
481
460
478
424
482

107
110
113
107
120
122
106
108
110
110
106
114
113
122
110
113
110
110
108
106
83
110
60
211

826
826
855
760
930
935
924
804
826
826
737
772
841
756
826
-832
826
--665
826
618
892

119
119
118
115
129
140
115
117
119
119
119
127
118
119
119
-121
119
--96
119
64
194
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4 DISCUSSION
In this study, we varied several parameters independently for 3 treatment geometries of
increasing complexity to determine their effect on resulting plan quality for VMAT treatment
planning. We found that most parameters had a small effect (<0.02 variation from baseline
values) on DHI and CI for both phantom and simple prostate cases and a larger effect (>0.02
variation from baseline values) on DHI and CI for the complex prostate case. Even though
greater than 0.02 variation from baseline DHI and CI values was found for most parameters for
the complex prostate case, the data was inconclusive of predictable trends for varying any
parameters other than total arc length. Similarly, the normal tissue metrics showed less than 3%
change for most parameters for the simple prostate case and greater than 3% change for the
complex prostate case with few predictable trends.
We observed that in effect, one can use a wide variety of values for any set of parameters
with very little change in the resulting plans for non-complex cases. In some instances, this is
because parameters are subject to an override by Pinnacle (i.e. maximum delivery time,
maximum gantry speed). We also speculate that because all parameters are optimized together,
there are enough degrees of freedom built into VMAT optimization to compensate for any one
parameter that would otherwise cause the optimization algorithm to struggle (i.e. maximum
gantry speed, maximum MLC leaf speed). This was especially true when varying
commissioning parameters for the two non-complex cases. For these reasons we have
determined that for non-complex treatment sites, SmartArc optimization is largely user-inputindependent and hardware independent, whereas complex treatment sites show a greater
dependency on input parameter values.
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4.1 Comparison to Previous Literature
Literature concerning how varying certain parameters affects the resulting plan quality is
limited. Su et al. used DMPO optimization for fixed-beam IMRT treatments to study the effects
of varying leaf width from 5mm to 1cm on resulting plan quality and accuracy (Su et al. 2007).
They concluded that leaf width showed no significant difference in CI or DHI for head and neck,
prostate, or spine geometries, but that there was slightly better dose accuracy for 1cm leaves.
Our study showed similar results for CI and DHI; all but one PTV (PTV3 of the complex
prostate case) had DHI changes of less than 2%, and the greatest difference in CI was only 3%
for the complex prostate case. The issue of beam energy has also been studied previously for
IMRT treatments. Pirzkall et al. showed that prostate IMRT treatments with less than 9 fields
could result in dose increases in tissues distant to the target volume (i.e. near the skin surface) for
lower energies (6MV), even though PTV and avoidance structure metrics were the same for 6,
10, and 18MV. Studies have also shown that with a greater number of fields (>9), the difference
between dose distributions for different beam energies disappears (Pirzkall et al. 2002; Fox et al.
2008). We found that there was no identifiable trend for increasing beam energy of VMAT
plans, but significant changes were seen in the DHI values of the complex prostate PTVs and the
CI and normal tissue metrics for all treatment geometries. However, we speculate that the
effects of beam energy may not translate directly from fixed-beam IMRT to VMAT treatment
plans, as the beam shape modulation is more restricted for VMAT planning.
While previous studies focus on one or two parameters of interest, we conducted a
systematic one dimensional examination of all the major VMAT parameters (commissioning and
planning) for geometries of varying complexity. This allowed us to provide information
comparing capabilities of different machines and different vendors. This study concludes that
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two major differences between Varian and Elekta machines (MLC leaf width and continuously
or discretely variable dose rates) are largely inconsequential.
4.2 Limitations and Future Work
There were several limitations to this study. First, only one parameter was varied at a
time, while all the others were held fixed. Possible interdependencies between the parameters
might have a larger effect on resulting plan quality if multiple parameters were changed
simultaneously. For example, the beam shape modulation between control points depends on
both the maximum MLC leaf speed and the maximum gantry speed. Varying several parameters
at once to study their combined effects on resulting plan quality could be valuable future
research. This could be done by randomly sampling a multi-dimensional complex space, as it
would be impossible to vary all parameters systematically (over 800,000 possible combinations
for the parameter values varied in this study).
In addition to varying multiple parameters together, it would be beneficial to investigate
how changing parameters effects plan accuracy, not just resulting plan quality. While this study
thoroughly investigated how each parameter effects the resulting DHI, CI, and dose metrics
calculated internally by the treatment planning system, it remains unknown how well the
calculated doses match what is actually being delivered by the treatment machine.
4.3 Clinical Relevance
Since the time this study was done, a clinical version (9.0) of Pinnacle including the
SmartArc module has been released, improving upon the research version (8.1y) by including
double arc capabilities and allowing the jaws to move with the MLC to provide additional
collimation. To check the clinical validity of the plans created using the research version, test
plans for the complex prostate case were run on Pinnacle 9.0. A new baseline plan was created
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Table 4-1. DHI and CI results for varying final gantry spacing on the research (8.1y)
and clinical (9.0) versions of Pinnacle.
Version
8.1y
9.0

Trial
4 deg
6 deg
4 deg
6 deg

DHI (PTV1)
0.16
0.19
0.15
0.18

DHI (PTV 2)
0.13
0.11
0.11
0.12

DHI (PTV 3)
0.61
0.63
0.57
0.61

DHI (PTV 4)
0.74
0.75
0.77
0.79

CI
0.79
0.67
0.83
0.83

on Pinnacle 9.0 that provided dose values equal to or better than those provided by the 8.1y
baseline plan. Trials were run for 4 degree and 6 degree final gantry spacing using Pinnacle 9.0,
and compared to the 4 degree and 6 degree trials run on Pinnacle 8.1y. The results for DHI and
CI for both versions of Pinnacle are shown in Table 4-1. The change in DHI from 4 degree final
gantry spacing to 6 degree final gantry spacing is similar for the research and clinical versions of
Pinnacle. The CI showed a change for the research version, but not for the clinical version. The
CI also performed better for the clinical version of Pinnacle.
4.4 Optimization Noise
We considered a 0.02 variation in DHI or CI values to be a significant change, and a 3%
difference in normal tissue metrics to be a significant change. These increments were based on
what we determined to be clinically significant changes. In other words, changes of this
magnitude would make one plan favorable to another in a clinical setting. In order to assess a
statistically significant difference, it was necessary to determine the uncertainty in the
optimization algorithm, or "optimization noise." To do this, very small changes were made to
the baseline plans for each treatment geometry, either to the original optimization goals or to the
dose grid resolution. These slightly modified plans were re-optimized and the doses recomputed. The trials for determining optimization noise by modifying an optimization goal are
described in Table 4-2. Dose grid resolution was also slightly modified to determine
optimization noise and dose calculation uncertainty. In trials 6 and 7 for the phantom, simple
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Table 4-2. Description of trials used to determine optimization noise by modifying an
optimization goal.
Geometry
Phantom
Simple Prostate

Complex Prostate

Trial

Weight

ROI

Type

Original Goal

New Goal

Trial 2

10

PTV

Max Dose

205

204

Trial 3

10

PTV

Max Dose

205

206

Trial 2

45

PTV

Min DVH

7600

7601

Trial 3

45

PTV

Min DVH

7600

7599

Trial 2

25

4620 only

Uniform

4620

4621

Trial 3

25

4620 only

Uniform

4620

4619

Trial 4

100

PTV 1

Uniform

7800

7801

Trial 5

100

PTV 1

Uniform

7800

7799

Table 4-3. Description of trials used to determine optimization noise and dose
calculation uncertainty by modifying the dose grid resolution.
Geometry

Phantom, Simple Prostate,
Complex Prostate

Trial 6

Reoptimization?
yes

Original Dose Grid
Resolution (cm)
0.400

New Dose Grid
Resolution (cm)
0.401

Trial 7

yes

0.400

0.399

Trial 8

no

0.400

0.401

Trial 9

no

0.400

0.399

Trial

prostate, and complex prostate cases, the dose grid resolution was changed to 0.401cm and
0.399cm, respectively, from the original resolution of 0.400cm. After the dose grid resolution
was modified for trials 6 and 7, plans were re-optimized and the dose was re-computed. The
dose grid resolution for trials 8 and 9 was modified similarly to trials 6 and 7, but the plans were
not re-optimized – only the dose was recomputed. Trials 6 and 7 are meant to show a combined
effect of optimization noise and dose calculation uncertainty, while trials 8 and 9 only show the
dose calculation uncertainty. Table 4-3 describes trials 6 through 9.
Results for determining optimization noise are shown in Table 4-4. Metrics used in the
study for all PTVs (DHI and CI) were normalized to the baseline values. The table shows the
difference between the values for DHI and CI for each trial and the baseline DHI and CI values
(EFGH%&'(%EIHJ. For trials 2-5 for all treatment geometries, the differences in DHI and CI were
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less than 0.002, the criteria for clinical significance. For trials 6 and 7 (re-optimization and recalculation of dose), the greatest difference in DHI was 0.04, and the greatest difference in CI
was 0.03. The average of all numbers in trials 6 and 7 was 0.013, which is less than the value for
clinical significance. DHI and CI values for trials 8 and 9 (no re-optimization) showed no
difference from the baseline DHI and CI values. Though there is undoubtedly both optimization
noise and dose calculation uncertainty in the treatment planning system, we determined that the
values for optimization and dose calculation uncertainty are less than our criteria for clinical
significance.
Table 4-4. Results for optimization noise. Values represent the change in DHI and CI
values from the baseline values for each trial.
Phantom
Trial

Simple Prostate

Complex Prostate
PTV1
!DHI
!CI

PTV2
!DHI

PTV3
!DHI

PTV4
!DHI

0.0

0.0

0.0

0.0

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.00

0.01

0.00

0.00

--

--

0.01

0.02

0.00

0.02

0.00

--

--

--

0.00

0.02

0.00

0.00

0.00

0.00

0.01

0.02

0.03

0.00

0.01

0.03

0.01

0.01

7

0.00

0.00

0.01

0.01

0.01

0.01

0.04

0.02

0.02

8

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

9

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

!DHI

!CI

!DHI

!CI

Baseline

0.00

0.00

0.00

0.00

0.0

2

0.00

0.01

0.00

0.00

3

0.00

0.00

0.00

4

--

--

5

--

6
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5 CONCLUSIONS
In conclusion, we used the Pinnacle SmartArc treatment planning module to
systematically examine the effects of varying parameters on resulting VMAT treatment plans.
The study was intentionally robust, allowing us to answer our initial hypothesis in a clinically
relevant way. We were able to create better than ±3% dose homogeneity in the PTV of a
phantom, and better than ±5% dose homogeneity in the PTV of a simple prostate patient for a
wide range of input parameter values, while keeping treatment times better than half of
corresponding fixed-beam IMRT plans. We were unable to achieve better than ±5% dose
homogeneity in the primary PTV of a complex prostate patient, though the baseline plan we
created was clinically acceptable and treatment times were still less than half of standard fixedbeam IMRT treatments. We found that SmartArc is largely user-independent and machine
hardware-independent for non-complex treatment geometries, but significant changes (>0.02
variation from baseline values for DHI and CI and >3% variation from baseline values for
normal tissue metrics) in plan quality can be seen when varying parameters for complex
geometries. This is useful information for centers when implementing protocols for VMAT
treatment planning or investigating which vendor provides the most compatible machine
hardware to their facility.

69

REFERENCES
Bortfeld T and Webb S 2009 Single-Arc IMRT? Phys Med Biol 54 N9-20
Bzdusek K, Friberger H, Erksson K, Hardenmark B, Robinson D and Kaus M 2009 Development and
evaluation of an efficient approach to volumetric arc therapy planning Med Phys 36 2328-39
Cao D, Holmes T W, Afghan M K and Shepard D M 2007 Comparison of plan quality provided by
intensity-modulated arc therapy and helical tomotherapy Int J Radiat Oncol Biol Phys 69 240-50
Earl M A, Shepard D M, Naqvi S, Li X A and Yu C X 2003 Inverse planning for intensity-modulated arc
therapy using direct aperture optimization Phys Med Biol 48 1075-89
Friberger H 2009 SmartArc in Pinnacle 9: A description of the algorithm RaySearch Laboratories
Fox C, Romeijn H E, Lynch B, Men C, Aleman D and Dempsey J 2008 Comparative analysis of 60Co
intensity-modulated radiation therapy Phys Med Biol 53 3175-88
Khan F M 2003 The physics of radiation therapy (Philadelphia: Lippincott Williams & Wilkins)
Lee T K, Rosen, II, Gibbons J P, Fields R S and Hogstrom K R 2008 Helical tomotherapy for parotid
gland tumors Int J Radiat Oncol Biol Phys 70 883-91
Mackie T R, Holmes T, Swerdloff S, Reckwerdt P, Deasy J O, Yang J, Paliwal B and Kinsella T 1993
Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy Med Phys 20 1709-19
Otto K 2008 Volumetric modulated arc therapy: IMRT in a single gantry arc Med Phys 35 310-7
Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, McKenzie M, Morris J and Otto K
2008 Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensitymodulated radiotherapy and three-dimensional conformal radiotherapy Int J Radiat Oncol Biol Phys 72
996-1001
Pirzkall A, Carol M P, Pickett B, Xia P, Roach M 3rd and Verhey L J 2002 The effect of beam energy
and number of fields on photon-based IMRT for deep-seated targets Int J Radiat Oncol Biol Phys 53 43442
Pollack A, Price R, Dong L, Feigenberg S and Horwitz E M 2005 Intact Prostate Cancer: Overview
Intensity Modulated Radiation Therapy: a clinical perspective eds. Mundt A and Roeske J 436-45
Reft C S, Runkel-Muller R and Myrianthopoulos L 2006 In vivo and phantom measurements of the
secondary photon and neutron doses for prostate patients undergoing 18 MV IMRT Med Phys 33 3734-42
Shah A P, Chen S S, Strauss J B, Kirk M C, Coleman J L, Coon A B, Miller C and Dickler A 2009 A
Dosimetric Analysis Comparing Treatment of Low-Risk Prostate Cancer With TomoTherapy Versus
Static Field Intensity Modulated Radiation Therapy Am J Clin Oncol
Shaffer R, Morris W J, Moiseenko V, Welsh M, Crumley C, Nakano S, Schmuland M, Pickles T, and
Otto K 2009 Volumetric Modulated Arc Therapy and Conventional Intensity-modulated Radiotherapy for
Simultaneous Maximal Intraprostatic Boost: a Planning Comparison Study Clin Oncol

70

Staffurth J 2010 A review of the clinical evidence for intensity-modulated radiotherapy Clin Oncol 22
643-57
Su Z, Kim S, Liu C and Palta J 2006 Is Dosimetric Effect of Leaf Width of MLC Clinically Significant in
IMRT IFMBE Proceedings eds. Kim S and Suh T S 14 1766-69
Svensson R, Kallman P and Brahme A 1994 An analytical solution for the dynamic control of multileaf
collimators Phys Med Biol 39 37-61
Verbakel W F, Cuijpers J P, Hoffmans D, Bieker M, Slotman B J and Senan S 2009 Volumetric intensitymodulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and
dosimetric study Int J Radiat Oncol Biol Phys 74 252-9
Webb S and McQuaid D 2009 Some considerations concerning volume-modulated arc therapy: a stepping
stone towards a general theory Phys Med Biol 54 4345-60
Wu Y, Yan D, Sharpe M B, Miller B and Wong J W 2001 Implementing multiple static field delivery for
intensity modulated beams Med Phys 28 2188-97
Yang J N, Mackie T R, Reckwerdt P, Deasy J O and Thomadsen B R 1997 An investigation of
tomotherapy beam delivery Med Phys 24 425-36
Yu C X 1995 Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to
tomotherapy Phys Med Biol 40 1435-49
Zhang P, Happersett L, Hunt M, Jackson A, Zelefsky M and Mageras G 2009 Volumetric modulated arc
therapy: planning and evaluation for prostate cancer cases Int J Radiat Oncol Biol Phys

71

VITA
The daughter of Tom Scott Talbert, Jr. and Elizabeth Kay Turner Talbert, Catharine
Elizabeth Talbert grew up in Wichita Falls, Texas. After graduating 9th in her class of 389 at
Rider High School in 2003, she went to Texas Christian University in Fort Worth, Texas, where
she studied mathematics and modern dance. In the fall of 2004, she transferred to Austin
College in Sherman, Texas. She majored in physics, minored in philosophy and received a
Bachelor of Arts degree in May, 2007. She entered the Medical Physics and Health Physics
Program at Louisiana State University in the fall of 2007 and will receive the Master of Science
degree in medical physics in 2010. She married Michael Haveman of Bloomington, Minnesota,
in April 2010.

72

